Joint venture · MENA · Announced 1 Jul 2020
Sinopharm → G42
Joint venture deal between Sinopharm (China) and G42 (United Arab Emirates), announced 1 Jul 2020.
Parties: Sinopharm (China) → G42 (United Arab Emirates)
- Deal type
- Joint venture
- Value
- Not stated
- Territory
- UAE (manufacturing base); Hayat-Vax exported to 64 countries
- Therapeutic area
- Vaccines
- Asset
- BBIBP-CorV inactivated vaccine ("Hayat-Vax"); later a recombinant protein-based booster
- Announced
- 1 Jul 2020
Our analysis
Why it matters
The corridor for China Pharma in MENA region began with localization, not import. The Sinopharm–G42 tie is remembered as the pandemic vaccine story, but for the tracker the defining feature is structure : not a distribution licence, but a JV that localized manufacturing.
In 2020, G42 and Sinopharm ran 4Humanity — the world's first Phase 3 trial of an inactivated COVID vaccine, ~43,000 volunteers across 125 nationalities in the Pan-Arab region.
The full analysis is free to read with a work email on this page.
Source: The National